Jing Christine Ye, MD, MSc
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1996 | Shanghai Jiao Tong University, Shanghai, CN, MSc |
| 1993 | Shanghai Jiao Tong University, Shanghai, CN, MD |
Postgraduate Training
| 2012-2015 | Clinical Fellowship, Hematology Oncology, Wayne State University, School of Medicine, Detroit, Michigan |
| 2009-2012 | Clinical Residency, Internal Medicine, Wayne State University, School of Medicine, Detroit, Michigan |
| 1996-1997 | Research Fellow, The Hospital for Sick Children, Toronto, Ontario |
Licenses & Certifications
| 2025 | State of Texas |
| 2016 | American Board of Internal Medicine- Hematology |
| 2015 | American Board of Internal Medicine- Oncology |
| 2012 | American Board of Internal Medicine |
| 2012 | State of Michigan |
Experience & Service
Faculty Academic Appointments
Associate Professor, Internal Medicine, Hematology Oncology, University of Michigan, Michigan Medicine, Ann Arbor, MI, 2021 - 2023
Assistant Professor, Internal Medicine, Hematology Oncology, University of Michigan, Michigan Medicine, Ann Arbor, MI, 2015 - 2021
Administrative Appointments/Responsibilities
Vice-Chair, NCI SWOG Multiple Myeloma Committee, 2022 - Present
Co-Chair, Big Ten Cancer Research Consortium (BTCRC), 2022 - 2023
Other Professional Positions
Research Associate, Wayne State University, Detroit, MI, 2003 - 2009
Chief Operating Officer, SeeDNA Biotech, Toronto/Windsor, 1997 - 2009
Intramural Institutional Committee Activities
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2025
Member, Scientific Review Committee (SRC), The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Credentialing Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Member, Pharmacy & Therapeutic Committee (PTC), The University of Texas MD Anderson Cancer Center, 2023 - Present
Extramural Institutional Committee Activities
Member, ASH Collaborative Research Initiative Myeloma Committee, American Society for Hematology (ASH), 2019 - 2023
Editorial Activities
Associate editor, Frontiers in Genetics, 2022 - Present
Topic Editor, Frontiers in Cell and Developmental Biology, 2021
Editorial Board Member, Molecular Cytogenetics (the official journal of the European Cytogeneticists Association), 2020 - 2024
Honors & Awards
| 2019 | SWOG Young Investigator Training Award |
| 2017 - 2018 | Clinical Trial Academy |
| 2012 | HONORS Research Award |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Bispecific Antibodies in Myeloma. Invited. July Lymphoma/Myeloma Monthly Education Series. Houston, Texas, US.
- 2026. SCTCT & Lymphoma/Myeloma Fellows Lecture- Christine Ye, MD. Invited. SCTCT & Lymphoma/Myeloma Fellows Lecture- Christine Ye, MD. Houston, Texas, US.
- 2026. Multiple Myeloma Updates: From CRAB to Immunotherapy. Invited. Monthly Conference. Houston, Texas, US.
- 2025. “Access & Advancement: Exploring Multiple Myeloma Resources and Research in Houston”. Panelist. Multiple Myeloma Research Foundation (MMRF) Community Connect. Houston, Texas, US.
- 2025. Clinical Trials in Multiple Myeloma- focus on Investigator Initiated and Cooperative Group trials. Invited. Myeloma Section Retreat. Houston, Texas, US.
- 2024. Expanding Service Horizons Through Myeloma Tissue Bank Innovations. Invited. Myeloma Tissue Bank Retreat. Houston, Texas, US.
- 2023. Early Relapse Multiple Myeloma. Invited. Myeloma Section Retreat. Houston, Texas, US.
Regional Presentations
- 2026. Incorporating GPRC5D-Targeting Therapiesin Multiple Myeloma Treatment. Invited. Regional Colloquium in Multiple Myeloma.
- 2026. Management of Patients with Smoldering Multiple Myeloma. Invited. Opinions in Multiple Myeloma. Fort Worth, Texas, US.
- 2026. Perceptions of Recent Data for Anti-CD38 Antibodies; Practical Considerations for Treatment Selection for Transplant-Ineligible/-Deferred Patients With NDMM. Anti-CD38-Containing Regimens Workshop. Houston, Texas, US.
- 2026. Optimizing Frontline Therapy in Multiple Myeloma. Invited. Regional Colloquium on Multiple Myeloma. Seattle, WA, US.
- 2025. Optimizing First-Line Therapy: How are Emerging Therapies Transforming Care in Newly Diagnosed Multiple Myeloma?. Invited. Onviv.
- 2025. “Updates on the Management of Plasma Cell Dyscrasias and Multiple Myeloma.”. Invited. 2025 ANACP 10th Annual Conference. Richardson, Texas, US.
- 2025. GPRC5D-targeting Bispecifics in Multiple Myeloma. Invited. Practical Considerations for Administering Bispecifics in the Community. Houston, TX, US.
- 2025. Panel Discussion. Panelist. Opinions in Multiple Myeloma. Woodlands, Texas, US.
- 2024. Frontline Quadruplet and Triplet Selection / Relapsed/Refractory Disease Management / Toxicity Mitigation & Peer Guidance. Invited. Targeted Oncology Community Case Forum. Frisco, Texas, US.
National Presentations
- 2026. Leadership summit - Medical Leadership & Innovation / Academic Career Progression / Multidisciplinary Practice Networks. Invited. 2026 ANACP 11th Annual Conference. Washington, District of Columbia, US.
- 2026. Bispecific T Cell Engagers in Multiple Myeloma: From Targets to Practice and Beyond. Invited. Plasma Cell Disorders Seminars. Milwaukee, Wisconsin, US.
- 2026. Updating the NCCN Clinical Practice Guidelines in Oncology for 2026/2027 - Refining Frontline Quadruplet Regimens / Standardizing Diagnostics and Plasmacytomas / Safety Mandates for Bispecific Antibodies / Formalizing Baseline NGS Storage. Invited. NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström Macroglobulinemia Panel Annual Meeting. West Conshohocken, Pennsylvania, US.
- 2026. Clinical strategies and real-world considerations for T-cell redirecting immunotherapies. Invited. 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop. Boston, Massachusetts, US.
- 2026. “Optimizing Frontline Therapy in Multiple Myeloma”. Invited. Regional Colloquium on Multiple Myeloma. Seattle, Washington, US.
- 2026. Management of Frail Newly Diagnosed Multiple Myeloma. Invited. Dogmas & Controversies in Hematologic Malignancies. Los Angeles, California, US.
- 2026. "ASH Highlights for Multiple Myeloma". Invited. Dogmas & Controversies in Hematologic Malignancies Conference. Los Angeles, California, US.
- 2026. ASH Highlights for Multiple Myeloma. Invited. Post-ASH 2025 Winter Symposium.
- 2025. Clinical data and therapeutic studies focused on improving treatment options for patients with advanced or high-risk multiple myeloma - Dual-Antigen Bispecific Antibody Targeting (RedirecTT-1 Study) / Real-World Outcomes of Talquetamab Monotherapy / Limited Duration of Bispecific Antibody Therapy. Invited. 67th American Society of Hematology (ASH) Annual Meeting & Exposition. Orlando, Florida, US.
- 2025. “Updates on the Management of Plasma Cell Dyscrasias and Multiple Myeloma”. Invited. 2025 ANACP 10th Annual Conference. Dallas, Texas, US.
- 2025. Clinical advancements in multiple myeloma, highlighting new combination regimens and long-term therapy data - The ADVANCE Clinical Trial (Abstract #7503). Invited. 2025 ASCO Annual Meeting. Chicago, Illinois, US.
- 2025. Clinical advancements in multiple myeloma, highlighting new combination regimens and long-term therapy data - MonumenTAL-1 Study Extended Follow-Up (Abstract #7528). Invited. 2025 ASCO Annual Meeting. Chicago, Illinois, US.
- 2025. "Treatment Advancements in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma". Invited. OncLive Peer Exchange - ASCO Updates Multiple Myeloma Discussions. Chicago, Illinois, US.
- 2025. Clinical Trial Protocol Development / Study Coordination Updates / Translational Medicine Initiatives. Invited. Spring 2025 SWOG Cancer Research Network Group Meeting. San Francisco, California, US.
- 2025. Vice-Chair of the SWOG Multiple Myeloma Committee - Clinical Trial Protocol Development / Study Coordination Updates / Translational Medicine Initiatives. Panelist. Spring 2025 SWOG Cancer Research Network Group Meeting. San Francisco, California, US.
- 2025. Career Tracks: Academic vs Community vs Industry vs Government/Policy / Key Decision Points and Trade-offs / Mentorship: Finding, Cultivating, Giving Back / Common Pitfalls and Lessons Learned. Panelist. 2025 CAHON Community Oncology Forum. Oxon Hill, Maryland, US.
- 2025. Co-Chair - Forum Leadership & Organization / The Academic-Community Interface / Oncology Career Roundtables. Invited. 2025 CAHON Community Oncology Forum. Oxon Hill, Maryland, US.
- 2025. Advances in Multiple Myeloma. Invited. Post-ASH 2024 Winter Symposium.
- 2024. Therapeutic strategies, combo safety tracking, and outcome data for advanced plasma cell disorders - RedirecTT-1 Study Cohorts / Real-World Teclistamab Delivery / Frontline Autologous HCT Registries. Invited. 66th American Society of Hematology (ASH) Annual Meeting & Exposition. San Diego, California, US.
- 2024. Session Moderation: "Current and Future Therapies for Multiple Myeloma". Invited. 11th Annual New York Oncology Forum (NYOF 2024). New York City, New York, US.
- 2024. Updates to network site investigators focused entirely on steering multi-center clinical trials - S1803 (DRAMMATIC) Progress / S2209 Trial Accrual / Lung-MAP Master Protocol Updates. Invited. Fall 2024 SWOG Cancer Research Network Group Meeting. Chicago, Illinois, US.
- 2024. Optimizing maintenance therapy options for post-transplant multiple myeloma patients - The Elotuzumab-Lenalidomide Maintenance Trial (Abstract #7509). Invited. 2024 ASCO Annual Meeting. Chicago, Illinois, US.
- 2024. Updates to network site coordinators focused on national clinical trial operations - S1803 (DRAMMATIC) Trial Execution / S2209 Protocol Implementation / New Protocol Concepts & Biomarkers. Invited. Spring 2024 SWOG Cancer Research Network Hybrid Group Meeting. Seattle, Washington, US.
- 2024. "Round Table Discussion: Myelodysplastic Syndrome". Panelist. 2024 CAHON Community Oncology Forum. Florida City, Florida, US.
- 2023. Multi-targeted immunotherapies, novel bispecific antibody schedules, and advanced mass spectrometry tracking for multiple myeloma - Dual-Antigen Target Efficacy (Abstract #1001) / Novel Bispecific Antibody Dosing & Sequencing / Mass Spectrometry for MRD Monitoring. Invited. 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
- 2023. CAR-T cell therapies, Antibody-Drug Conjugates (ADCs), and Bispecific T-cell Engagers (BiTEs). Invited. 10th Annual New York Oncology Forum (NYOF). New York City, New York, US.
- 2023. Updating and driving national clinical trial infrastructure. Invited. SWOG Fall Group Meeting. Chicago, Illinois, US.
- 2023. Advancing treatment outcomes and defining genetic sub-types in plasma cell malignancies - Dual-Antigen Clinical Targeting (The RedirecTT-1 Study) / High-Risk Genome Chaos Mapping / Real-World Efficacy Reviews (The TAURUS Registry Data). Invited. 18th International Myeloma Workshop (IMW 2023). Detroit, Michigan, US.
- 2023. Advanced, targeted immunotherapies for heavily pre-treated blood cancers - Core Presentation Focus: The LINKER-MM1 Study. Invited. 2023 ASCO Annual Meeting. Chicago, Illinois, US.
- 2023. Active Protocol Portfolio Review / Pipeline Concept Development / Multi-Institutional Coordination. Invited. Spring 2023 SWOG Hybrid Group Meeting. San Francisco, California, US.
- 2023. High-risk genomic classifications in multiple myeloma - Evaluating structural chromosomal rearrangements and large-scale genomic alterations in plasma cell malignancies. Invited. 2023 AACR Annual Meeting. Orlando, Florida, US.
- 2022. Multiple Myeloma Updates. Conference. Multiple Myeloma Updates. Chicago, IL, US.
- 2022. Minimal Residual Disease in Multiple Myeloma. Conference. Minimal Residual Disease in Multiple Myeloma, US.
- 2022. 2022 Hematology Highlights: A Post ASH Review. A New Era of Immunotherapy in Multiple Myeloma. Conference. 2022 Hematology Highlights: A Post ASH Review. A New Era of Immunotherapy in Multiple Myeloma. Omaha, NE, US.
- 2021. A New Era in Multiple Myeloma Treatment. Conference. A New Era in Multiple Myeloma Treatment. Newport News, VA, US.
- 2021. New Paradigm of Frontline Treatment in Newly Diagnosed Multiple Myeloma. Conference. Institutional Perspectives in Cancer, US.
- 2020. Post-ASH Winter Symposium: Advances in Multiple Myeloma. Conference. Post-ASH Winter Symposium: Advances in Multiple Myeloma, US.
- 2020. Multiple Myeloma Management Case Discussions. Panelist. Community Oncology Forum.
- 2019. 2019 Updates for Multiple Myeloma Management. Conference. 2019 Updates for Multiple Myeloma Management, FL, US.
- 2019. How to Establish a Clinical Research Portfolio. Conference. How to Establish a Clinical Research Portfolio. New York, NY, US.
- 2019. How to Manage Newly Diagnosed Multiple Myeloma?. Conference. How to Manage Newly Diagnosed Multiple Myeloma?. Detroit, MI, US.
International Presentations
- 2026. BCMA-Targeted Bispecifics Biology and Clinical Applications in Multiple Myeloma. Invited. Bispecific Virtual Symposium. Navi Mumbai, IN.
- 2026. Managing high-risk myeloma disease types and tracking long-term data for advanced immunotherapies - Extended-Interval Dosing for Multi-Specifics. Invited. 31st European Hematology Association (EHA) Annual Congress. Stockholm, SE.
- 2026. Managing high-risk myeloma disease types and tracking long-term data for advanced immunotherapies - Extended-Interval Dosing for Multi-Specifics / Clinical Trial Design for Extramedullary Disease / Updated Consensus Criteria for Solitary Plasmacytomas. Invited. 2026 International Myeloma Working Group (IMWG) Annual Summit. Stockholm, SE.
- 2026. BCMA-Targeted Bispecific Antibodies in Multiple Myeloma. Invited. Indian Bispecific Virtual Symposium. Navi Mumbai, IN.
- 2025. "Updated Comparative Effectiveness of Talquetamab vs Real-World Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma". Invited. 22nd International Myeloma Society (IMS) Annual Meeting & Exposition. Toronto, CA.
- 2025. Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma. Invited. IACH Journal Club. Paris, FR.
- 2025. Formulating Immune Therapy Committee consensus guidelines for managing toxicities linked to T-cell-engaging bispecific antibodies - Reviewing multi-center safety datasets to refine clinical response criteria and establish proactive mitigation rules for Cytokine Release Syndrome (CRS) and neurological toxicities (ICANS). Invited. 2025 International Myeloma Working Group (IMWG) Annual Summit. Milan, IT.
- 2025. MRD-Guided Maintenance Therapy (Abstract #PF754) - Long-term clinical survival outcomes of patients with Waldenström macroglobulinemia (WM) who were forced to discontinue Bruton's tyrosine kinase inhibitor (BTKI) therapies (like ibrutinib). Invited. 30th European Hematology Association (EHA) Annual Congress. Milan, IT.
- 2025. Waldenström Macroglobulinemia Analysis (Abstract #PS1890) - An interim analysis of a Phase II trial testing MRD-guided maintenance therapy using belantamab mafodotin combined with lenalidomide in newly diagnosed multiple myeloma patients after receiving an autologous stem cell transplant (auto-HCT). Invited. 30th European Hematology Association (EHA) Annual Congress. Milan, IT.
- 2025. Chromoanagenesis, a subtype of genome chaos, in multiple myeloma: integrating clinical data with optical genomic mapping. Conference. Controversies in Multiple Myeloma (COMy). Paris, FR.
- 2025. Invited Educational Track: Clinical Trial Operations - "Clinical Trials in Multiple Myeloma—focus on Investigator Initiated and Cooperative Group trials". Invited. 11th World Congress on Controversies in Multiple Myeloma (COMy). Paris, FR.
- 2025. Main Session Presentation: High-Risk Cytogenetics - "Chromoanagenesis, a subtype of genome chaos, in multiple myeloma: integrating clinical data with optical genomic mapping". Invited. 11th World Congress on Controversies in Multiple Myeloma (COMy). Paris, FR.
- 2025. Navigating New Frontiers of High-Risk Multiple Myeloma Management in the beginning of 2025. Invited. KOL Expert Seminars. Bridgewater, US.
- 2024. “Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma: An International Myeloma Working Group (IMWG) Immunotherapy Registry Analysis”. Invited. Chinese Medical Doctor Association (CMDA) 8th Academic Conference on Multiple Myeloma. Beijing, CN.
- 2024. "Updated Comparative Effectiveness of Talquetamab vs Real-World Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma". Invited. 21st International Myeloma Society (IMS) Annual Meeting & Exposition. Rio de Janeiro, BR.
- 2024. Minimal Residual Disease (MRD) guided myeloma treatment. Invited. 3rd Translational Summit on HEMATOLOGIC MALIGNANCIES, BM.
- 2024. “Minimal Residual Disease (MRD) guided myeloma treatment”. Invited. 3rd Annual Bermuda Translational Summit on Hematologic Malignancies.
- 2024. Finding better clinical pathways for high-risk and advanced relapsed/refractory multiple myeloma (RRMM) - Meta-Analysis on Extramedullary Myeloma Outcomes (Abstract #P922). Invited. 2024 European Hematology Association (EHA) Annual Congress. Madrid, ES.
- 2024. Finding better clinical pathways for high-risk and advanced relapsed/refractory multiple myeloma (RRMM) - Long-Term Data on GPRC5D Bispecific Antibodies (Abstract #P915). Invited. 2024 European Hematology Association (EHA) Annual Congress. Madrid, ES.
- 2024. IMWG global panel: Immunotherapy Committee Recommendations / Managing Aggressive and High-Risk Malignancies / Toxicity Mitigation for T-Cell Redirecting Platforms. Panelist. 15th Annual International Myeloma Working Group (IMWG) Summit. Madrid.
- 2023. "Progression-Free Survival of Daratumumab vs. Other Standard-of-Care Frontline Regimens in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Multi-Center Chart Review Study (TAURUS)". Invited. 20th International Myeloma Society (IMS) Annual Meeting & Exposition. Athens, US.
Formal Peers
- 2025. Current T Cell Engagers (TCE) in Multiple Myeloma: Practical Insights. Houston, Texas, US.
- 2020. Decipher Genes, Chromosomes and Novel Therapeutic Strategies in Multiple Myeloma. Invited, US.
- 2018. Step Into Immuno-Oncology in Multiple Myeloma. Invited, US.
Grant & Contract Support
| Date: | 2026 - Present |
| Title: | RADIANT-EMD: Radiotherapy-Augmented Immune Activation with Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma with Extramedullary Disease (EMD) |
| Funding Source: | Department of War (previously DOD) |
| Role: | PI |
| Date: | 2026 - Present |
| Title: | IMPACT-M3 SPORE Project3 |
| Funding Source: | NIH |
| Role: | Co-PI |
| Date: | 2026 - Present |
| Title: | PRIME-EMD2: A Phase 2 Study of Radiotherapy-Induced Immune Priming to Enhance Elranatamab/Mezigdomide in Relapsed Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD) |
| Funding Source: | Cancer Prevention and & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Immune Atlas Program: Gene Expression Profiling of the Bone Marrow Microenvironment in Multiple Myeloma |
| Funding Source: | Multiple Myeloma Research Foundation (MMRF) |
| Role: | PI |
| Date: | 2023 - Present |
| Title: | Comprehensive Cytogenomic Profiling in Multiple Myeloma: Augmenting Risk Stratification and Treatment Response Prediction |
| Funding Source: | Cancer Prevention And Research Institute Of Texas Individual Investigator Research Awards (CPRIT) |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | Moonshot High Risk Multiple Myeloma Project 2: Observational Study of Genomic and Immune Predictors for Progression to Multiple Myeloma |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2022 - 2024 |
| Title: | Decipher Immune Signatures and Therapeutic Response in Multiple Myeloma Patients |
| Funding Source: | The Joint Institute for Translational and Clinical Research |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | M-Cube Grant: Functional and clinically relevant T/NK cell subset screening from deep immune profiling in multiple myeloma |
| Funding Source: | University of Michigan |
| Role: | PI |
| Date: | 2018 - 2023 |
| Title: | Clinical-Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies |
| Funding Source: | Multiple Myeloma Research Foundation |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Rasche L, Schinke C, Touzeau C, Minnema MC, van de Donk N, Rodriguez-Otero P, Mateos MV, Ye JC, Tomlinson C, Vishwamitra D, Singh I, Qin X, Campagna M, Masterson T, Vreys V, Lau BW, Tolbert J, Renaud T, Heuck C, Chari A. Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. Blood, 2026. e-Pub 2026. PMID: 42561120.
- Bashir Q, Thall PF, Kawedia J, Xu X, Knape CG, Delgado R, Nieto Y, Saini NY, Aljawai YM, Srour SA, Ramdial JL, Hosing C, Popat UR, Oran B, Kebriaei P, Ahmed S, Pasvolsky O, Patel KK, Thomas SK, Gaballa MR, Ye JC, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200. Blood Adv, 2026. e-Pub 2026. PMID: 42537695.
- Afrough A, Pasvolsky O, Portuguese AJ, Zanwar S, Gaballa MR, Sannareddy A, Dima D, Goel U, Ali HM, Julian K, Silva Corraes ADM, Janakiram M, Goldsmith S, Davis JA, Green K, Biran N, Fogel L, Zolotov E, Herr MM, Hassan H, Shune L, Kort J, Ye C, Bal S, Costa LJ, Joiner L, Hadidi SA, Khan AM, Raza S, Anwer F, Khouri J, Banerjee R, Cassano RC, Sidana S, Rana MS, Mikkilineni L, Hosoya H, Atrash S, Ferreri C, Varga C, Sborov DW, Midha S, Nadeem O, Grajales-Cruz A, Baz R, Blue B, Freeman C, Locke FL, Patel KK, Lin Y, Kumar SK, Hansen DK, Anderson Jr LD, Voorhees PM, Castaneda-Puglianini O. Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium. Blood Cancer Journal, 2026. e-Pub 2026.
- Dang M, Moreno Rueda LY, Acevedo Calado MJ, Bansal H, Berrios Nolasco DA, Vora AU, Mejia JD, Huang M, Tan W, Qin L, Liu Y, Liu Y, Mery DE, Cheng Y, Zhan F, Shaughnessy JD, Yi Q, Lin P, Gaballa MR, Pasvolsky O, Lee HC, Thomas SK, Weber DM, Patel KK, Becnel MR, Ye JC, Kuiatse I, Manasanch EE, Wang L, Orlowski RZ. Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma. Blood, 2026. e-Pub 2026. PMID: 42413006.
- Gaballa MR, Julian K, Afrough A, Hansen DK, Goel U, De Menezes Silva Corraes A, Dima D, Rana MS, Hosoya H, Mikkilineni L, Fogel L, Raza S, Banerjee R, Zanwar SS, Pasvolsky O, Sannareddy A, Borogovac A, Davis JA, Green K, Biran N, Zolotov E, Herr MM, Shune L, Bhurtel E, DeJarnette S, Atrash S, Ferreri CJ, Richards T, Abid MB, Bal S, Ali HM, Ye JC, Richard S, Kaur G, Shain KH, Castaneda-Puglianini OA, Harada K, De Avila G, Rossi AC, Hassan H, Anderson LD Jr, Voorhees P, Khouri J, Sidana S, Portuguese AJ, Janakiram M, Lee HC, Lin Y, Grajales-Cruz AF, Patel KK, Sborov DW. Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia. Blood Adv, 2026. e-Pub 2026. PMID: 42392158.
- Mina R, Beksac M, Rodriguez-Otero P, Chen W, Mateos MV, Li J, Moreau P, Cohen YC, Min CK, Jelinek T, Ye JC, Magen H, Rubinstein SM, Fu W, Hungria V, Cengiz Seval G, Farias JS, Radocha J, Maral S, Turgut M, Koh Y, O'Leary D, Schmidt Filho J, Thertulien R, An G, Huang SY, Grosicki S, Tyczynska A, Banerjee R, Pianko MJ, Martinez-Lopez J, Steckiewicz P, Maruyama D, Fukushima K, Oriol A, Lopez Pardo J, Goldschmidt H, Pawlyn C, Perrot A, Zamagni E, Dimopoulos MA, Rasche L, Tolbert J, Terry W, Courtoux C, Liu X, Vasey SY, Connors K, Festa M, Heuck C, Langlois A, O'Rourke L, Zhou J, Qin X, Lu J, Gong J, Vieyra D, Voorhees PM. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. N Engl J Med, 2026. e-Pub 2026. PMID: 42294841.
- Horne, S, Ye, JC, Liu, G, Abdallah, BY, Stevens, JB, Heng, H. Therapy-induced rapid drug resistance driven by genome chaos and polyploid giant cancer cells. Cancer Letters 645, 2026. e-Pub 2026. PMID: 41763449.
- Ye, JC, Biran, N, Nair, S, Lin, X, Qi, K, Ammann, E, Renaud, T, Lau, BW, Zhang, J, Parekh, T, Gray, K, Zhang, X, Costa, LM. Relative Effectiveness of Talquetamab Versus Real-World Physician’s Choice Treatment Regimens in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia 26(4):e525-e535.e3, 2026. e-Pub 2026. PMID: 41565510.
- Ye, JC, Chowdhury, R, Heng, H. Conversation with Future Clinical Cytogeneticists. Genes 17(2), 2026. e-Pub 2026. PMID: 41751616.
- Haider AA, Marcoux C, Milton DR, Tanner MR, Bashir Q, Smallbone P, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Siddiqui UR, Aljawai Y, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation. Leuk Lymphoma:1-9, 2026. e-Pub 2026. PMID: 41608977.
- Kumar, SK, Callander, N, Adekola, K, Anderson, L, Baljevic, M, Baz, R, Campagnaro, E, Costello, C, D’Angelo, C, Derman, B, Devarakonda, S, Elsedawy, N, Godara, A, Godby, K, Hillengass, J, Holmberg, L, Htut, M, Huff, CA, Hultcrantz, M, Kang, Y, Larson, S, Lee, HC, Liedtke, M, Martin, TG, Omel, J, Robinson, TJ, Rosenberg, AS, Sarosiek, S, Schroeder, MA, Sherbenou, D, Suvannasankha, A, Valent, J, Varshavsky-Yanovsky, AN, Vogl, DT, Ye, JC, Kovach, E, Kumar, R. Multiple Myeloma, Version 5.2026. JNCCN Journal of the National Comprehensive Cancer Network 24(1), 2026. e-Pub 2026. PMID: 41671464.
- Kumar S, Richter J, Usmani SZ, Cohen YC, Ye JC, Mateos MV, Hungria V, Zamagni E. Extramedullary Disease-Achilles Heel in Myeloma?. Am J Hematol 101(3):521-536, 2025. e-Pub 2025. PMID: 41462032.
- Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodriguez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosinol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC. Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab. N Engl J Med 394(1):51-61, 2025. e-Pub 2025. PMID: 41358582.
- Voorhees PM, Kumar S, Usmani SZ, Ye JC, Cohen YC, Scott E, Carson RL, Heuck C, Gan R, Ackerman B, Zhang J, Caplan E, Parekh T, Mateos MV. Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis. Ann Hematol 104(12):6263-6274, 2025. e-Pub 2025. PMID: 41335212.
- Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK. Long-term outcomes and treatment patterns in Waldenstrom macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. Blood Cancer J 15(1):211, 2025. e-Pub 2025. PMID: 41340003.
- Lee HC, Zonder JA, Dhodapkar MV, Jagannath S, Hoffman JE, Suvannasankha A, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martinez-Lopez J, DeVeaux M, Roccia T, Chokshi D, Seraphin M, Knorr K, Boyapati A, Hazra A, Rodriguez Lorenc K, Kroog GS, Bumma N, Richter J. Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. Clin Lymphoma Myeloma Leuk 26(2):e201-e212.e8, 2025. e-Pub 2025. PMID: 41387038.
- van de Donk NWCJ, Chari A, Martin T, Krishnan A, Rasche L, Ye JC, Popat R, Lipe B, Rodriguez C, Schinke C, Skerget S, Vishwamitra D, Verona R, Gong J, Singh I, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Smit MD, Heuck C, Mateos MV. Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma. Cancer Med 14(19):e71276, 2025. e-Pub 2025. PMID: 41036677.
- Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai Y, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplant Cell Ther 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
- Chari, A, Touzeau, C, Schinke, C, Minnema, MC, Berdeja, JG, Oriol, A, Van De Donk, NW, Rodríguez-Otero, P, Morillo, D, Martinez-Chamorro, C, Mateos, MV, Costa, LM, Caers, J, Rasche, L, Krishnan, A, Ye, JC, Karlin, L, Lipe, B, Vishwamitra, D, Skerget, S, Verona, R, Ma, X, Qin, X, Ludlage, H, Campagna, M, Masterson, T, Hilder, BW, Tolbert, J, Renaud, T, Goldberg, JD, Kane, C, Heuck, C, San Miguel, JF, Moreau, P. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1). The Lancet Haematology 12(4):e269-e281, 2025. e-Pub 2025. PMID: 40090350.
- Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
- Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia 39(3):543-554, 2025. e-Pub 2025. PMID: 39870767.
- Horwitz SM, Feldman TA, Ye JC, Khodadoust MS, Munoz J, Hamlin PA, Kim YH, Wilcox RA, Patel MR, Coffey G, Innes A, Betz A, Holland J, Guzman CB, Smith SM. Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. Leuk Lymphoma:1-11, 2025. e-Pub 2025. PMID: 39921522.
- Ye JC, Biran N, Nair S, Lin X, Qi K, Londhe A, Ammann E, Renaud T, Kane C, Parekh T, Gray K, Peterson S, Costa LJ. Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 25(2):124-134.e5, 2025. e-Pub 2025. PMID: 39271448.
- Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Kebriaei, P, Aljawai, YM, Khan, HN, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38760362.
- Manzar GS, Dudzinski SO, Yoder AK, Seo A, Nasr LF, Rafei H, Becnel MR, Patel KK, Lee HC, Kaufman GP, Gaballa MM, Ye JC, Saini N, Thomas SK, Amini B, Orlowski RZ, Dabaja BS, Pinnix CC, Gunther JR, Wu SY, Fang PQ. Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy. Clin Lymphoma Myeloma Leuk, 2024. e-Pub 2024. PMID: 39709251.
- Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R, Lipe B, Qin X, Campagna M, Masterson T, Tomlinson C, Hilder B, Tolbert J, Renaud T, Smit MD, Gray K, Kane C, Heuck C, van de Donk NWCJ. Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab. Clin Lymphoma Myeloma Leuk 24(10):665-693.e14, 2024. e-Pub 2024. PMID: 38871558.
- Bumma, N, Richter, J, Jagannath, S, Lee, HC, Hoffman, JE, Suvannasankha, A, Zonder, J, Shah, M, Lentzsch, S, Baz, R, Maly, J, Namburi, S, Pianko, M, Ye, JC, Wu, KL, Silbermann, R, Min, CK, Vekemans, MC, Munder, M, Byun, JM, Martinez-Lopez, J, Cassady, K, DeVeaux, M, Chokshi, D, Boyapati, A, Hazra, A, Yancopoulos, G, Sirulnik, LA, Rodriguez-Lorenc, K, Kroog, G, Houvras, Y, Dhodapkar, M. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology 42(22):2702-2712, 2024. e-Pub 2024. PMID: 38879802.
- Zou YS, Klausner M, Ghabrial J, Stinnett V, Long P, Morsberger L, Murry JB, Beierl K, Gocke CD, Xian RR, Toomer KH, Ye JC, Orlowski RZ, Huff CA, Ali SA, Imus PH, Gocke CB, Tang G. A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping. Blood Cancer J 14(1):78, 2024. e-Pub 2024. PMID: 38702349.
- Rodríguez-Otero, P, Usmani, S, Cohen, AD, Van De Donk, NW, Leleu, X, Pérez-Larraya, JG, Manier, S, Nooka, AK, Mateos, MV, Einsele, H, Minnema, MC, Cavo, M, Derman, B, Puig, N, Gay, F, Ho, J, Chng, WJ, Kastritis, E, Gahrton, G, Weisel, K, Nagarajan, C, Schjesvold, F, Mikhael, J, Costa, LM, Raje, N, Zamagni, E, Hajek, R, Weinhold, N, Yong, K, Ye, JC, Sidhana, S, Merlini, G, Martin, T, Lin, Y, Chari, A, Popat, R, Kaufman, JL. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. The lancet oncology 25(5):e205-e216, 2024. e-Pub 2024. PMID: 38697166.
- Stino, AM, Bumma, N, Smith, R, Davalos, L, Allen, J, Ye, JC, Pianko, M, Campagnaro, E, Fierro, C, Awad, A, Murdock, B, Pietrzak, M, Loszanski, G, Kline, DM, Efebera, Y, Elsheikh, B. Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy. European Journal of Neurology 31(3), 2024. e-Pub 2024. PMID: 38015467.
- Ye, JC, Heng, H. Tracking Karyotype Changes in Treatment-Induced Drug-Resistant Evolution:263-280, 2024. e-Pub 2024. PMID: 38913315.
- Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, Fu AZ, Lafeuille MH, Thompson-Leduc P, Khare V, Reitan J, Milkovich G, Kaila S, Davies F, Usmani SZ. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. Clin Lymphoma Myeloma Leuk 24(1):55-63, 2024. e-Pub 2024. PMID: 37838502.
- Tang G, Wu Y, Lin P, Toruner GA, Hu S, Li S, Qazilbash MH, Orlowski RZ, Ye C, Xu J, Nahmod KA, Medeiros LJ, Tang Z. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells. Cancers (Basel) 15(23), 2023. e-Pub 2023. PMID: 38067393.
- Janakiram M, Ye JC. Role of Anti–CD38 Antibody Therapy in Induction and Maintenance in Newly Diagnosed Multiple Myeloma: How to Adopt in Clinical Practice. ASCO Daily News, 2023. e-Pub 2023.
- Sankar, K, Ye, JC, Li, Z, Zheng, L, Song, W, Hu-Lieskovan, S. The role of biomarkers in personalized immunotherapy. Biomarker Research 10(1), 2022. e-Pub 2022. PMID: 35585623.
- Vo JN, Wu YM, Mishler J, Hall S, Vats P, Mannan R, Wang L, Ning Y, Zhou J, Hopkins AC, Estill J, Chan WKB, Yesil J, Cao X, Rao A, Tsodikov A, Talpaz M, Cole CE, Ye JC, Bergsagel L, Auclair D, Robinson DR, Chinnaivan AM. The Genetic Heterogeneity and Drug Resistance Mechanisms of Relapsed Refractory Multiple Myeloma. Nat Commun 13(1):3750, 2022. e-Pub 2022. PMID: 35768438.
- Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN Guidelines(R) Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw 20(6):622-634, 2022. e-Pub 2022. PMID: 35714675.
- Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. Journal of hemotology and oncology 14(1):115, 2021. e-Pub 2021. PMID: 34301270.
- Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol 14(1):66, 2021. e-Pub 2021. PMID: 33879198.
- Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies. J Hematol Oncol 14(1):66, 2021. e-Pub 2021. PMID: 33879198.
- Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell R, Holstein S, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jkubowiak A, Morgan GJ, a K, Jacson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, San Miguel J, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International Harmonization in Performing and Reporting Minimal Residual Disease Assessment in Multiple Myeloma Trials. Leukemia, 2021. e-Pub 2021. PMID: 32778736.
- Ye JC, Horne S, Zhang JZ, Jackson L, Heng HH. Therapy Induced Genome Chaos: A Novel Mechanism of Rapid Cancer Drug Resistance. Front Cell Dev Biol 9:676344, 2021. e-Pub 2021. PMID: 34195196.
- Ye JC, Sharpe Z, Heng HH. Origins and Consequences of Chromosomal Instability: From Cellular Adaptation to Genome Chaos-Mediated System Survival. Genes (Basel) 11(10):1162, 2020. e-Pub 2020. PMID: 33008067.
- Ye JC, Chen J, Liu G, Heng HH. Somatic Genomic Mosaicism in Multiple Myeloma. Front Genet 11:388, 2020. e-Pub 2020. PMID: 32391059.
- Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, Campagnaro E, Nachar VR. Optimal Sequence Of Daratumumab And Elotuzumab In Relapsed And Refractory Multiple Myeloma. Leuk Lymphoma 61(3):691-698, 2020. e-Pub 2020. PMID: 31739729.
- Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, Campagnaro E, Nachar VR. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma 61(3):691-698, 2020. e-Pub 2020. PMID: 31739729.
- Ye CJ, Chen J, Liu G, Heng HH. Somatic Genomic Mosaicism in Multiple Myeloma. Front Genet 11:388, 2020. e-Pub 2020. PMID: 32391059.
- Ye JC, Stilgenbauer L, Moy A, Liu G, Heng HH. What Is Karyotype Coding and Why Is Genomic Topology Important for Cancer and Evolution?. Front Genet 10:1082, 2019. e-Pub 2019. PMID: 31737054.
- Modi D, Ye JC, Surapaneni M, Singh V, Chen W, Jang H, Deol A, Ayash L, Alavi A, Ratanatharathorn V, Uberti JP. Liver Graft-Versus-Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients. Am J Hematol 94(10):1072-1080, 2019. e-Pub 2019. PMID: 31292984.
- Skala SL, Ye JC, Stumph J, Macon WR, Quinones FR, Khachaturov V, Ketterling RP, Dewar R. Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma. Clin Pathol, 2019. e-Pub 2019. PMID: 31633108.
- Ye CJ, Sharpe Z, Alemara S, Mackenzie S, Liu G, Abdallah B, Horne S, Regan S, Heng HH. Micronuclei and Genome Chaos: Changing the System Inheritance. Genes (Basel) 10(5), 2019. e-Pub 2019. PMID: 31086101.
- Ye JC, Sharpe Z, Alemara S, Mackenzie S, Liu G, Abdallah B, Horne S, Regan S, Heng HH. Micronuclei and Genome Chaos: Changing the System Inheritance. Genes 10(5):366, 2019. e-Pub 2019. PMID: 31086101.
- Modi D, Ye JC, Surapaneni M, Singh V, Chen W, Jang H, Deol A, Ayash L, Alavi A, Ratanatharathorn V, Uberti JP. Liver Graft-Versus-Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients. Am J Hematol 94(10):1072-1080, 2019. e-Pub 2019. PMID: 31292984.
- Ye CJ, Stilgenbauer L, Moy A, Liu G, Heng HH. What Is Karyotype Coding and Why Is Genomic Topology Important for Cancer and Evolution?. Front Genet 10:1082, 2019. e-Pub 2019. PMID: 31737054.
- Ye JC, Regan S, Liu G, Alemara S, Heng HH. Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems. Mol Cytogenet 11:31, 2018. e-Pub 2018. PMID: 29760781.
- Heng HH, Horne SD, Chaudhry S, Regan SM, Liu G, Abdallah BY, Ye CJ. A Postgenomic Perspective on Molecular Cytogenetics. Curr Genomics 19(3):227-239, 2018. e-Pub 2018. PMID: 29606910.
- Heng HH, Horne SD, Chaudhry S, Regan SM, Liu G, Abdallah BY, Ye CJ. A Postgenomic Perspective on Molecular Cytogenetics. Curr Genomics 19(3):227-239, 2018. e-Pub 2018. PMID: 29606910.
- Liu G, Ye CJ, Chowdhury SK, Abdallah BY, Horne SD, Nichols D, Heng HH. Detecting Chromosome Condensation Defects in Gulf War Illness Patients. Curr Genomics 19(3):200-206, 2018. e-Pub 2018. PMID: 29606907.
- Ye CJ, Liu G, Heng HH. Experimental Induction of Genome Chaos. Methods Mol Biol 1769:337-352, 2018. e-Pub 2018. PMID: 29564834.
- Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 77:65, 2018. e-Pub 2018. PMID: 30408566.
- Ye CJ, Regan S, Liu G, Alemara S, Heng HH. Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems. Mol Cytogenet 11:31, 2018. e-Pub 2018. PMID: 29760781.
- Ye CJ, Heng HH. High Resolution Fiber-Fluorescence In Situ Hybridization. Methods Mol Biol 1541:151-166, 2017. e-Pub 2017. PMID: 27910022.
- Heng HH, Regan SM, Liu G, Ye CJ. Why It Is Crucial to Analyze Non Clonal Chromosome Aberrations Or NCCAs?. Mol Cytogenet 9:15, 2016. e-Pub 2016. PMID: 26877768.
- Stevens JB, Liu G, Abdallah BY, Horne SD, Ye KJ, Bremer SW, Ye CJ, Krawetz SA, Heng HH. Unstable genomes elevate transcriptome dynamics. Int. J. Cancer 134(9):2074-2087, 2014. e-Pub 2014. PMID: 24122714.
- Abdallah BY, Horne SD, Kurkinen M, Stevens JB, Liu G, Ye CJ, Barbat J, Bremer SW, Heng HH. Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer. Syst Biol Reprod Med 60(1):2-13, 2014. e-Pub 2014. PMID: 24147962.
- Liu G, Stevens JB, Horne SD, Abdallah BY, Ye KJ, Bremer SW, Ye CJ, Chen DJ, Heng HH. Genome chaos: Survival strategy during crisis. Cell Cycle 13(4):528-537, 2014. e-Pub 2014. PMID: 24299711.
- Stevens JB, Horne SD, Abdallah BY, Ye CJ, Heng HH. Chromosomal instability and transcriptome dynamics in cancer. Cancer Metastasis Rev 32(3-4):391-402, 2013. e-Pub 2013. PMID: 23595307.
- Heng HH, Bremer SW, Stevens JB, Horne SD, Liu G, Abdallah BY, Ye KJ, Ye CJ. Chromosomal instability (CIN): What it is and why it is crucial to cancer evolution. Cancer Metastasis Rev 32(3-4):325-340, 2013. e-Pub 2013. PMID: 23605440.
- Stevens JB, Abdallah BY, Liu G, Horne SD, Bremer SW, Ye KJ, Huang JY, Kurkinen M, Ye CJ, Heng HH. Heterogeneity of cell death. Cytogenet. Genome Res 139(3):164-173, 2013. e-Pub 2013. PMID: 23548436.
- Heng HH, Liu G, Stevens JB, Abdallah BY, Horne SD, Ye KJ, Bremer SW, Chowdhury SK, Ye CJ. Karyotype heterogeneity and unclassified chromosomal abnormalities. Cytogenet Genome Res 139(3):144-57, 2013. e-Pub 2013. PMID: 23571381.
- Horne SD, Stevens JB, Abdallah BY, Liu G, Bremer SW, Ye CJ, Heng HH. Why imatinib remains an exception of cancer research. J. Cell. Physiol 228(4):665-670, 2013. e-Pub 2013. PMID: 23018746.
- Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Abdallah BY, Horne SD, Ye CJ. Decoding the genome beyond sequencing: The new phase of genomic research. Genomics 98(4):242-252, 2011. e-Pub 2011. PMID: 21640814.
- Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, Savasan S, Shekhar M, Krawetz SA, Hüttemann M, Tainsky MA, Wu GS, Xie Y, Zhang K, Heng HH. Diverse system stresses: Common mechanisms of chromosome fragmentation. Cell Death Dis 2(6):89, 2011. e-Pub 2011. PMID: 21716293.
- Chandrakasan S, Ye CJ, Chitlur M, Mohamed AN, Rabah R, Konski A, Heng HH, Savaşan S. Malignant fibrous histiocytoma two years after autologous stem cell transplant for Hodgkin lymphoma: evidence for genomic instability. Pediatr Blood Cancer 56(7):1143-5, 2011. e-Pub 2011. PMID: 21488163.
- Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ. Evolutionary Mechanisms and Diversity in Cancer Adv. Cancer Res 112:217-253, 2011. e-Pub 2011. PMID: 21925306.
- Stevens JB, Abdallah BY, Regan SM, Liu G, Bremer SW, Ye CJ, Heng HH. Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation. Mol Cytogenet 3(1):58, 2010. e-Pub 2010. PMID: 20959006.
- Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Ye CJ. Genetic and epigenetic heterogeneity in cancer: The ultimate challenge for drug therapy. Curr Drug Targets 11(10):1304-1316, 2010. e-Pub 2010. PMID: 20840073.
- Heng HH, Stevens JB, Bremer SW, Ye KJ, Liu G, Ye CJ. The evolutionary mechanism of cancer. J. Cell. Biochem 109(6):1072-1084, 2010. e-Pub 2010. PMID: 20213744.
- Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: A genome-centric perspective. J. Cell. Physiol 220(3):538-547, 2009. e-Pub 2009. PMID: 19441078.
- Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, Lin MF, Lawrenson L, Lancaster WD, Kurkinen M, Liao JD, Gairola CG, Shekhar MP, Narayan S, Miller FR, Heng HH. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol 219(2):288-300, 2009. e-Pub 2009. PMID: 19115235.
- Heng HH, Stevens JB, Lawrenson L, Liu G, Ye KJ, Bremer SW, Ye CJ. Patterns of genome dynamics and cancer evolution. Cell. Oncol 30(6):513-514, 2008. e-Pub 2008. PMID: 18936532.
- Stevens JB, Liu G, Bremer SW, Ye KJ, Xu W, Xu J, Sun Y, Wu GS, Savasan S, Krawetz SA, Ye CJ, Heng HH. Mitotic cell death by chromosome fragmentation. Cancer Res 67(16):7686-7694, 2007. e-Pub 2007. PMID: 17699772.
- Ye CJ, Liu G, Bremer SW, Heng HH. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res 118(2-4):237-46, 2007. e-Pub 2007. PMID: 18000376.
- Heng HH, Bremer SW, Stevens J, Ye KJ, Miller F, Liu G, Ye CJ. Cancer progression by non-clonal chromosome aberrations. J. Cell. Biochem 98(6):1424-1435, 2006. e-Pub 2006. PMID: 16676347.
- Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky MA, Ye CJ. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 208(2):461-72, 2006. e-Pub 2006. PMID: 16688757.
- Heng HH, Liu G, Bremer S, Ye KJ, Stevens J, Ye CJ. Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome 49(3):195-204, 2006. e-Pub 2006. PMID: 16604101.
- Ye CJ, Stevens JB, Liu G, Ye KJ, Yang F, Bremer SW, Heng HH. Combined multicolor-FISH and immunostaining. Cytogenet Genome Res 114(3-4):227-34, 2006. e-Pub 2006. PMID: 16954658.
- Heng HH, Goetze S, Ye CJ, Liu G, Stevens JB, Bremer SW, Wykes SM, Bode J, Krawetz SA. Chromatin loops are selectively anchored using scaffold/matrix-attachment regions. J. Cell. Sci 117(7):999-1008, 2004. e-Pub 2004. PMID: 14996931.
- Heng HH, Stevens JB, Liu G, Bremer SW, Ye CJ. Imaging genome abnormalities in cancer research. Cell Chromosome 3(1):1, 2004. e-Pub 2004. PMID: 14720303.
- Heng HH, Ye CJ, Yang F, Ebrahim S, Liu G, Bremer SW, Thomas CM, Ye J, Chen TJ, Tuck-Muller C, Yu JW, Krawetz SA, Johnson A. Analysis of marker or complex chromosomal rearrangements present in pre- and post-natal karyotypes utilizing a combination of G-banding, spectral karyotyping and fluorescence in situ hybridization. Clin Genet 63(5):358-67, 2003. e-Pub 2003. PMID: 12752567.
- Takeuchi T, Heng HH, Ye CJ, Liang SB, Iwata J, Sonobe H, Ohtsuki Y. Down-regulation of a novel actin- binding molecule, skeletrophin, in malignant melanoma. Am J Pathol 163(4):1395-404, 2003. e-Pub 2003. PMID: 14507647.
- Schmid C, Heng HH, Rubin C, Ye CJ, Krawetz SA. Sperm nuclear matrix association of the PRM1-- >PRM2-->TNP2 domain is independent of Alu methylation. Mol Hum Reprod 7(10):903-11, 2001. e-Pub 2001. PMID: 11574659.
- Heng HH, Liu G, Lu W, Bremer S, Ye CJ, Hughes M, Moens P. Spectral karyotyping (SKY) of mouse meiotic chromosomes. Genome 44(2):293-8, 2001. e-Pub 2001. PMID: 11341740.
- Heng HH, Krawetz SA, Lu W, Bremer S, Liu G, Ye CJ. Re-defining the chromatin loop domain Cytogenet. Cell Genet 93(3-4):155-161, 2001. e-Pub 2001. PMID: 11528105.
- Ye CJ, Lu W, Liu G, Bremer SW, Wang YA, Moens P, Hughes M, Krawetz SA, Heng HH. The combination of SKY and specific loci detection with FISH or immunostaining. Cytogenet Cell Genet 93(3-4):195-202, 2001. e-Pub 2001. PMID: 11528112.
- Omori F, Messner HA, Ye JC, Gronda MV, O'Neill JP, Atkins H, Heng HH. Nontargeted stable integration of recombinant adeno-associated virus into human leukemia and lymphoma cell lines as evaluated by fluorescence in situ hybridization. Hum Gene Ther 10(4):537-43, 1999. e-Pub 1999. PMID: 10094197.
- Tarsounas M, Heng HH, Ye JC, Pearlman RE, Moens PB. Identification of the mouse beta'-COP Golgi component as a spermatocyte autoantigen in scleroderma and mapping of its gene Copb2 to mouse chromosome 9. Cytogenet Cell Genet 87(3-4):201-4, 1999. e-Pub 1999. PMID: 10702668.
- Ye J, Cao Q, Su X, Huang Q, Ma Z, Wang Z, Huang W, Chen Z, Chen S. Biological and clinical significance of cytogenic study on 100 acute lymphoblastic leukemia and 219 acute non-lymphoblastic leukemia. Chin Med J (Engl) 110(2):90-5, 1997. e-Pub 1997. PMID: 9594276.
- Chen SJ, Cao Q, Ma ZG, Su XY, Xong SM, Ye J, Wang ZY, Li XS, Shen ZX, Zhang FQ, Sun GL, Fang ZW, Ouyang RR, Zhu XH, Ying DM, Gu LJ, Chen Z. Cytogenic analysis and its prognostic significance in acute non-lymphoblastic leukemia. Chinese Journal of Hematology, 1996. e-Pub 1996.
- Mao M, Yu M, Tong JH, Ye J, Zhu J, Huang QH, Fu G, Yu L, Zhao SY, Waxman S, Lanotte M, Wang ZY, Tan JZ, Chan SJ, Chen Z. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocyctic leukemia cell. Proc Natl Acad Sci U S A:5910-4, 1996. e-Pub 1996. PMID: 8650192.
Abstracts
- Ye JC, Chen L, Chen J, Parkin B, Polk A, Kandarpa M, Cole CE, Campagnaro EL, Robinson D, Wu YM, Talpaz M, Yesil J, Auclair D, Bergsagel PL, Chinnaiyan A, Baladandayuthapani V. Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients 134:4360, 2019. e-Pub 2019.
Book Chapters
- Ye, JC, Tang, G. Optical Genome Mapping, 113-124, 2024.
- Ye, JC, Heng, H. The New Era of Cancer Cytogenetics and Cytogenomics, 2024.
- Ye, JC, Heng, H. Preface. In: Cancer Cytogenetics and Cytogenomics. Humana, v-vi, 2024.
- Chen J, Ye JC. Chronic Lymphocytic Leukemia. In: Oncology Board Review. 3. DemosMedical - An Imprint of Springer Publishing, 2021.
- Ye, JC, Regan, S, Liu, G., Abdallah, B., Horne, S., Heng, H.H.. Unclassified Chromosome Abnormalities and Genome Behavior in Interphase. In: Human Interphase Chromosomes. 2. Springer Cham, 107-130, 2020.
- Heng, H.H,, Liu, G, Alemara, S., Regan, S., Armstrong, Z., Ye, J.C.. The Mechanisms of How Genomic Heterogeneity Impacts Bio-Emergent Properties: The Challenges for Precision Medicine. In: Embracing Complexity in Health. Springer, Cham, 2019.
- Heng HH, Liu G, Ye JC. Experimental Induction of Genome Chaos. In: Methods Mol Biol, 337-352, 2018.
- Ye JC, Heng HH. High Resolution Fiber-Fluorescence In Situ Hybridization. In: Methods Mol Biol Protocols and Applications, 151-166, 2017.
- Ye JC, Liu G, Heng HH. Simultaneous Fluorescence Immunostaining and FISH. In: Fluorescence In Situ Hybridization (FISH). Springer Berlin, Heidelberg, 301-325, 2016.
- Ye JC, Lawrenson L, Liu G, Stevens JB, Ye KJ, Bremer SW, Heng HH. Simultaneous fluorescence immunostaining and FISH. In: Fluorescence in situ hybridization (FISH) Application. 1. Springer Berlin, Heidelberg, 193-216, 2009.
Books (edited and written)
- Ye, J. C., Heng, H. H.. Cancer Cytogenetics and Cytogenomics (Methods in Molecular Biology Series). Springer Nature/Humana Press, 2024.
Patient Reviews
CV information above last modified August 21, 2026